Nurix Therapeutics, Inc.
corporate_fare Company Profile
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for NRIX at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Nurix Therapeutics Details Strong Clinical Progress for Lead Candidates & Substantial Funding in Annual Report
- Nurix Therapeutics Reports Strong Bexobrutideg Phase 1 Data, Initiates Pivotal Phase 2, and Plans Phase 3 Trial
- Nurix Therapeutics Initiates Pivotal Phase 2 for Bexobrutideg in CLL, Reports Strong Data & Outlines 2026 Goals
Financial Snapshot
Fiscal year ended November 30, 2025
Revenue
$83.98M
Net Income
-$264.46M
Diluted EPS
-$3.05
Op. Cash Flow
-$249.47M
Free Cash Flow
-$263.47M
Operating Income
-$285.67M
Cash & Equivalents
$246.96M
Debt / Equity
0.00×
Net Margin
-314.9%
Shares Outstanding
101.81M sh
Source: 10-K · filed 2026-01-28 · accession 0001549595-26-000016
show_chartPrice Chart
Loading chart...
feed NRIX - Filings & News (Page 2)
NRIX
Jan 28, 2026, 4:09 PM EST
Price at Filing:
$17.87
Real-time Price:
$12.85
Change:
-$5.02 (-28%)
Market Cap:
$1.404B
NRIX
Jan 28, 2026, 4:03 PM EST
Price at Filing:
$17.87
Real-time Price:
$12.85
Change:
-$5.02 (-28%)
Market Cap:
$1.404B
NRIX
Jan 12, 2026, 8:34 AM EST
Price at Filing:
$19.49
Real-time Price:
$12.85
Change:
-$6.64 (-34%)
Market Cap:
$1.404B